Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005–2018)
-
Published:2023-01
Issue:1
Volume:1
Page:3-11
-
ISSN:2949-7132
-
Container-title:Cancer Pathogenesis and Therapy
-
language:en
-
Short-container-title:Cancer Pathogenesis and Therapy
Author:
Shi YuankaiORCID, Chen Haizhu, Qin Yan, Yang Jianliang, Liu Peng, He Xiaohui, Zhou Shengyu, Zhou Liqiang, Zhang Changgong, Song Yongwen, Liu Yueping, Gui Lin, Wang Shulian, Jin Jing, Fang Hui, Qi Shunan, Li Ning, Tang Yu, Wang Xin, Yang Sheng
Reference38 articles.
1. A clinical evaluation of the international lymphoma study group classification of non-hodgkin's lymphoma. The non-hodgkin's lymphoma classification project;Blood,1997 2. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011;Al-Hamadani;Am J Hematol,2015 3. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification;Sun;Am J Clin Pathol,2012 4. Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution;Yang;Diagn Pathol,2011 5. Advanced diffuse histiocytic lymphoma, a potentially curable disease;DeVita;Lancet,1975
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|